Cargando…

Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial

BACKGROUND: Skin prick testing is the most important diagnostic tool to detect immunoglobulin E-mediated allergic diseases. With increase in the number of allergy tests performed in India, it is imperative to know the potency of indigenous extracts in comparison with U.S. Food and Drug Administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopher, Devasahayam J., Ashok, Narmada, Ravivarma, Aruna, Shankar, Deepa, Peterson, Erik, Dinh, Phuong T., Vedanthan, P. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156211/
https://www.ncbi.nlm.nih.gov/pubmed/30263870
http://dx.doi.org/10.1177/2152656718796746
_version_ 1783358055870627840
author Christopher, Devasahayam J.
Ashok, Narmada
Ravivarma, Aruna
Shankar, Deepa
Peterson, Erik
Dinh, Phuong T.
Vedanthan, P. K.
author_facet Christopher, Devasahayam J.
Ashok, Narmada
Ravivarma, Aruna
Shankar, Deepa
Peterson, Erik
Dinh, Phuong T.
Vedanthan, P. K.
author_sort Christopher, Devasahayam J.
collection PubMed
description BACKGROUND: Skin prick testing is the most important diagnostic tool to detect immunoglobulin E-mediated allergic diseases. With increase in the number of allergy tests performed in India, it is imperative to know the potency of indigenous extracts in comparison with U.S. Food and Drug Administration (USFDA)-approved extracts. METHODS: A randomized comparison trial of Indian manufactured and USFDA-approved extracts of Dermatophagoides pteronyssinus (DP) and Dermatophagoides farinae (DF) was done at Christian Medical College & Hospital, Vellore, India from April 2014 to June 2015, to compare the skin test reactivity of indigenous allergen extracts of dust mites against validated allergen. Study enrollment included 197 patients with allergic disorders that showed sensitivity to dust mite during routine allergy skin testing. Study participants were tested with varying dilutions of DP and DF indigenous extracts along with USFDA-approved allergens in a blinded fashion. Results were recorded, and statistical significance was calculated using the Friedman rank sum test. RESULTS: Using the Friedman rank sum test with a Tukey adjustment for multiple comparisons, we found that the extracts in each dilution were significantly different (P < .0001). The full strength indigenous extracts, B-DF (DF allergen standard extract from Bioproducts and Diagnostics, India) and C-DF (DF allergen extract from Creative Diagnostics, India) extracts, had mean wheal sizes of 7.69 (standard deviation [SD] 9.91) and 31.01(SD 51.04), respectively. The full strength S-DF (DF allergen extract from Jubilant Hollister Stier, Spokane, WA, USA) had a mean wheal size of 109.97 (SD 162.73), which was significantly higher (P < .0001) than both the indigenous extracts. For each of the dilutions, the S-DF mean wheal size was significantly greater than that of the corresponding B-DF and C-DF wheal sizes. The full strength indigenous C-DP (DP allergen extract from Creative Diagnostics, India) had mean wheal size of 39.37 (SD 51.74). The full strength standard S-DP (DP allergen extract from Jubilant Hollister Stier, Spokane, WA, USA) extract had a mean wheal size of 167.66 (SD 270.80), which was significantly higher (P < .0001) than the indigenous C-DP extract. Similar differences were seen across all dilutions. CONCLUSION: The indigenous extracts have significantly lower potency compared to USFDA-approved extracts; hence, there is an urgent need for policy makers to institute stringent criteria for standardization of antigens in India.
format Online
Article
Text
id pubmed-6156211
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61562112018-09-27 Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial Christopher, Devasahayam J. Ashok, Narmada Ravivarma, Aruna Shankar, Deepa Peterson, Erik Dinh, Phuong T. Vedanthan, P. K. Allergy Rhinol (Providence) Article BACKGROUND: Skin prick testing is the most important diagnostic tool to detect immunoglobulin E-mediated allergic diseases. With increase in the number of allergy tests performed in India, it is imperative to know the potency of indigenous extracts in comparison with U.S. Food and Drug Administration (USFDA)-approved extracts. METHODS: A randomized comparison trial of Indian manufactured and USFDA-approved extracts of Dermatophagoides pteronyssinus (DP) and Dermatophagoides farinae (DF) was done at Christian Medical College & Hospital, Vellore, India from April 2014 to June 2015, to compare the skin test reactivity of indigenous allergen extracts of dust mites against validated allergen. Study enrollment included 197 patients with allergic disorders that showed sensitivity to dust mite during routine allergy skin testing. Study participants were tested with varying dilutions of DP and DF indigenous extracts along with USFDA-approved allergens in a blinded fashion. Results were recorded, and statistical significance was calculated using the Friedman rank sum test. RESULTS: Using the Friedman rank sum test with a Tukey adjustment for multiple comparisons, we found that the extracts in each dilution were significantly different (P < .0001). The full strength indigenous extracts, B-DF (DF allergen standard extract from Bioproducts and Diagnostics, India) and C-DF (DF allergen extract from Creative Diagnostics, India) extracts, had mean wheal sizes of 7.69 (standard deviation [SD] 9.91) and 31.01(SD 51.04), respectively. The full strength S-DF (DF allergen extract from Jubilant Hollister Stier, Spokane, WA, USA) had a mean wheal size of 109.97 (SD 162.73), which was significantly higher (P < .0001) than both the indigenous extracts. For each of the dilutions, the S-DF mean wheal size was significantly greater than that of the corresponding B-DF and C-DF wheal sizes. The full strength indigenous C-DP (DP allergen extract from Creative Diagnostics, India) had mean wheal size of 39.37 (SD 51.74). The full strength standard S-DP (DP allergen extract from Jubilant Hollister Stier, Spokane, WA, USA) extract had a mean wheal size of 167.66 (SD 270.80), which was significantly higher (P < .0001) than the indigenous C-DP extract. Similar differences were seen across all dilutions. CONCLUSION: The indigenous extracts have significantly lower potency compared to USFDA-approved extracts; hence, there is an urgent need for policy makers to institute stringent criteria for standardization of antigens in India. SAGE Publications 2018-09-25 /pmc/articles/PMC6156211/ /pubmed/30263870 http://dx.doi.org/10.1177/2152656718796746 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Christopher, Devasahayam J.
Ashok, Narmada
Ravivarma, Aruna
Shankar, Deepa
Peterson, Erik
Dinh, Phuong T.
Vedanthan, P. K.
Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title_full Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title_fullStr Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title_full_unstemmed Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title_short Low Potency of Indian Dust Mite Allergen Skin Prick Test Extracts Compared to FDA-Approved Extracts: A Double-Blinded Randomized Control Trial
title_sort low potency of indian dust mite allergen skin prick test extracts compared to fda-approved extracts: a double-blinded randomized control trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156211/
https://www.ncbi.nlm.nih.gov/pubmed/30263870
http://dx.doi.org/10.1177/2152656718796746
work_keys_str_mv AT christopherdevasahayamj lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT ashoknarmada lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT ravivarmaaruna lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT shankardeepa lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT petersonerik lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT dinhphuongt lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial
AT vedanthanpk lowpotencyofindiandustmiteallergenskinpricktestextractscomparedtofdaapprovedextractsadoubleblindedrandomizedcontroltrial